following a full submission assessed under the end of life and orphan equivalent medicine process:
trifluridine/tipiracil (Lonsurf®) is accepted for use within NHSScotland.
Indication under review: in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
In an open-label, randomised phase III study, the addition of bevacizumab to trifluridine/tipiracil was associated with significant improvements in overall survival.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- trifluridine tipiracil (Lonsurf)
- SMC ID:
- SMC2654
- Indication:
In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 August 2024